glp 1 trials Cardiovascular outcomes in major with GLP-1 receptor agonists Discovery of GLP-1–Based Drugs for

Structural Confirmation Mass spectrometry (LC-MS) verifies molecular weight and structural integrity of each compound

The recent work by Telorack et al

GLP-1 medications reduce inflammation and improve metabolic health, which can decrease chronic immune activation, one of the major drivers of accelerated aging in people with HIV

This further prevents other complications which present secondarily to obesity, such as kidney disease, cardiovascular disease, and liver disease

69 Potential mechanisms include decreased intestinal lipid production, reduced intestinal triglyceride absorption due to lowered secretion of apoB48-containing chylomicrons, smaller postprandial triglyceride secretion and effects on the expression of genes involved in lipid metabolism